Investigational Drug Information for ICP-022
✉ Email this page to a colleague
What is the drug development status for ICP-022?
ICP-022 is an investigational drug.
There have been 16 clinical trials for ICP-022.
The most recent clinical trial was a Phase 1 trial, which was initiated on January 8th 2021.
The most common disease conditions in clinical trials are Lymphoma, Lymphoma, B-Cell, and Leukemia, Lymphoid. The leading clinical trial sponsors are Beijing InnoCare Pharma Tech Co., Ltd., Innocare Pharma Australia Pty Ltd, and Shandong University.
There is one US patent protecting this investigational drug and forty international patents.
Summary for ICP-022
| US Patents | 1 |
| International Patents | 40 |
| US Patent Applications | 19 |
| WIPO Patent Applications | 13 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2021-01-08) |
| Vendors | 34 |
Recent Clinical Trials for ICP-022
| Title | Sponsor | Phase |
|---|---|---|
| A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 3 |
| Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Primary Central Nervous System Lymphoma | Henan Cancer Hospital | Phase 2 |
Clinical Trial Summary for ICP-022
Top disease conditions for ICP-022
Top clinical trial sponsors for ICP-022
International Patents for ICP-022
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| ICP-022 | Australia | AU2014324595 | 2033-10-16 | ⤷ Sign Up |
| ICP-022 | Canada | CA2925624 | 2033-10-16 | ⤷ Sign Up |
| ICP-022 | China | CN104341388 | 2033-10-16 | ⤷ Sign Up |
| ICP-022 | Denmark | DK3052476 | 2033-09-30 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
